Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
37.8M
-
Number of holders
-
98
-
Total 13F shares, excl. options
-
30.1M
-
Shares change
-
+302K
-
Total reported value, excl. options
-
$481M
-
Value change
-
+$6.08M
-
Put/Call ratio
-
0.48
-
Number of buys
-
62
-
Number of sells
-
-26
-
Price
-
$15.98
Significant Holders of Entrada Therapeutics, Inc. - COMMON STOCK (TRDA) as of Q3 2024
109 filings reported holding TRDA - Entrada Therapeutics, Inc. - COMMON STOCK as of Q3 2024.
Entrada Therapeutics, Inc. - COMMON STOCK (TRDA) has 98 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.1M shares
of 37.8M outstanding shares and own 79.72% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (4.87M shares), MPM ASSET MANAGEMENT LLC (4.43M shares), 5AM Venture Management, LLC (4.41M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.05M shares), BlackRock, Inc. (1.82M shares), FMR LLC (1.74M shares), JANUS HENDERSON GROUP PLC (1.71M shares), VANGUARD GROUP INC (1.22M shares), WELLINGTON MANAGEMENT GROUP LLP (1.03M shares), and StepStone Group LP (761K shares).
This table shows the top 98 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.